The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why.
FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.
Lipid-lowering medication may be an effective adjuvant cancer therapy.
Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.
Study: Single Dose Radiotherapy Equally Effective as Conventional Radiotherapy for Most Breast Cancer Cases
The authors concluded that a single dose of targeted intraoperative radiotherapy should be an option accessible to health care providers and discussed with patients.
Filgrastim Found to be Cost Effective as Primary Prophylaxis for Febrile Neutropenia in Breast Cancer Patients
Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.
Patients should talk to their health care team about when to reschedule a postponed or cancelled screening appointment.
Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.
Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.
First New Drug in Years Reduces Recurrence in High-Risk Hormone Receptor Positive Early Breast Cancer
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
Study shows the recurrence rate was within the expected range for breast cancer survivors receiving spironolactone and those who did not.